Diagnostic and prognostic value of the methylation status of secreted frizzledrelated protein 2 in colorectal cancer
Results: Methylated SFRP2 was frequently detected in CRC tissues and precancerous lesions. e sensitivity of SFRP2 methylation levels in tissue, fecal and serum DNA for the detection of CRC was similar, ranging from 66.9 to 88.2%; however, serum SFRP2 methylation levels showed a markedly higher speci city in discriminating CRCs from benign adenomas than those of SFRP2 methylation levels in tumor and fecal DNA. Moreover, serum SFRP2 methylation was signi cantly associated with poor di erentiation grade (P=0.019), serosal/subserosal invasion (P<0.001), lymph node metastasis status (P<0.001) and TNM stage (P<0.001) of CRC. CRC patients with SFRP2 hypermethylation in tumor, stool and serum samples had a signi cantly shorter overall survival than those negative for SFRP2 methylation (P=0.0216, 0.0219, and 0.0255, respectively). Multivariate Cox regression analysis revealed that SFRP2 promoter methylation in tumor samples was an independent prognostic factor for overall survival.
Conclusion:
Our data suggest that serum SFRP2 methylation status represents a promising, non-invasive marker for CRC detection and staging. Hypermethylated SFRP2 may have prognostic relevance in patients with CRC.
Colorectal cancer (CRC) is the third most common malignancy worldwide and the second leading cause of cancerrelated death in Western countries [1, 2] . is malignancy develops as a result of the transformation of normal colon epithelium to cancer via a stepwise histological progression sequence, proceeding from either adenomas or hyperplastic polyps/ serrated adenomas [3, 4] . Detection of early stage CRC and precancerous lesions has great promise to improve clinical outcomes and reduce mortality [5, 6] . Yet, currently available noninvasive methods, such as fecal occult blood testing and measurement of serum carcinoembryonic antigen (CEA) levels, have low sensitivities and/or speci cities for colorectal cancer [7] [8] [9] [10] . erefore, there is an urgent need to identify novel molecular markers in diagnosing and monitoring of this malignancy.
Epigenetic inactivation of tumor-related genes due to hypermethylation of CpG islands in the promoter region plays a key role in colorectal cancer carcinogenesis [3, 11, 12] . Examination of the aberrantly methylated gene promoter may thus be of value in distinguishing between malignant and benign tumors. Solid malignant tumors have been well documented to release signi cant amounts of DNA into the circulation system [13, 14] . e tumor released DNA may represent a noninvasive biomarker for cancer detection. Indeed, assessment of aberrant DNA methylation in serum and fecal samples has been proposed as a promising high-throughput approach for the screening and monitoring of CRC [15] [16] [17] .
Secreted frizzled-related proteins (SFRPs) comprise a family of secreted glycoproteins that function as inhibitive modulators of a putative tumorigenic pathway-the Wnt signaling pathway [18] . ey contain an N-terminal cysteine-rich domain homologous to the putative Wnt-binding site of frizzled receptors, but lack a transmembraneous region as well as a C-terminal domain required for intracellular signal transduction [19] . e unique structure of SFRPs enables them to bind and sequester Wnt molecules from their cognate frizzled receptors, thus interfering with the Wnt pathway. Loss of SFRP2 expression due to promoter methylation has been frequently observed in many tumors, including colorectal, ovarian, breast, gastric and liver cancers [17, [20] [21] [22] [23] . Several earlier studies have demonstrated that the frequency of SFRP2 promoter methylation in fecal DNA is markedly increased in CRC patients compared with normal healthy controls [24] [25] , suggesting the SFRP2 hypermethylation in fecal DNA as a potential molecular biomarker of CRC. In this study, we extended the previous work and systematically evaluated the diagnostic potentials of SFRP2 promoter methylation in tumor tissue, stool and serum DNA samples in CRC. e prognostic value of SFRP2 hypermethylation was also assessed in CRC patients.
Materials and Methods
e study was approved by the Ethical Committee of Yangzhou University (Yangzhou, China), and written informed consent was obtained from each study participant. Fresh tissue samples, including 169 cases of sporadic CRCs, 63 advanced adenomas, 46 hyperplastic polyps and 30 macroscopically normal colorectal mucosas, were collected at surgery or endoscopy from the First A liated Hospital of Yangzhou University. A er removal, the tissue samples were immediately snap-frozen in liquid nitrogen and stored at -80ºC. None of the sporadic CRC patients had received chemotherapy or radiation therapy prior to surgery. Haematoxylin and eosin staining was performed on all the samples for con rmation of diagnosis. CRC was staged according to the TNM classi cation system, and histological grade was assessed following the Broders' grading system. Advanced adenoma was de ned as size ≥1 cm or having villous histology or high-grade dysplasia [26] . Stool samples were obtained from all participants a er commencing bowel preparation the day before colonoscopy in a self-collection manner. Within 12 hours a er collection, the samples were washed once with phosphate-bu ered saline (PBS), centrifuged and stored at -80ºC. Five milliliters of whole blood were withdrawn from each participant. Serum was obtained by centrifugation at 3000 × g for 15 min at 4ºC and stored at -80ºC until analysis.
DNA was isolated from colonic tissues (5-10 mg), stool samples (250 mg), and serum samples (200 μl) using QIAamp DNA Mini Kit, QIAamp DNA Stool Mini Kit, and QIAamp Blood Mini Kit (Qiagen, Hilden, Germany), respectively, according to the manufacturer's protocols,. Bisul te treatment of the extracted DNA was performed using the EpiTect® Bisul te Kit (Qiagen), which converts unmethylated cytosines to uracils while leaving methylated cytosines unaltered.
e bisul temodi ed DNA was subjected to methylation-speci c polymerase chain reaction (MS-PCR) for detection of the methylation status of the CpG-rich region (-219 to -81 relative to the transcription start site) in the SFRP2 promoter, as described previously [27] .
e aberrant methylation of this region is linked to transcriptional silencing of SFPR2 in tumor cells. e MS-PCR primers are listed in Supplementary Table 1 . Template-free distilled water was included as a negative control Tang et al. Clinical signi cance of SFRP2 methylation in CRC for the PCR. DNA from normal peripheral blood lymphocytes (PBL) was used as a control for the unmethylated SFRP2 promoter, while Sss I methylase-treated DNA from PBL served as a positive control for the methylated SFRP2 promoter. e success rate for the MS-PCR was approximately 99%. e PCR products were analyzed by electrophoresis in 2.5% agarose gels and stained with ethidium bromide.
Statistical analysis
Statistical analyses were performed using SPSS10.0 so ware (SPSS, Chicago, IL, USA). e correlation between SFRP2 methylation and clinicopathologic features of CRC was analyzed with the χ 2 test. Overall survival was assessed using Kaplan-Meier curves with the log-rank test. Multivariate analysis, using a Cox proportional hazards model, was performed to identify prognostic factors associated with overall survival. P values of less than 0.05 were considered statistically signi cant.
Results e methylation status of SFRP2 gene in DNA samples was determined from distinct solid tissue samples. e MS-PCR assay revealed that methylated SFRP2 gene was most frequently detected in the CRC tissue specimens (149/169, 88.2%), followed by advanced adenoma (41/63, 65.1%) and non-adenomatous polyp (21/46, 45.7%) ( Table 1 ). In contrast, none of the normal colorectal mucosas showed SFRP2 hypermethylation (Table 1; Figure 1) .
Next, the SFRP2 methylation status in the stool and serum DNA samples was measured and compared with that observed in the corresponding solid tissue DNA samples (Figure 1 ). Similar to in the matched solid tissue DNA samples, SFRP2 hypermethylation was frequently found in the fecal and serum DNA samples of CRC patients, although to a slightly lesser extent (Table 1) . Patients with adenoma and non-adenomatous polyp showed a marked lower frequency of SFRP2 hypermethylation in the fecal and particularly serum DNA samples. To evaluate the diagnostic relevance of SFRP2 methylation, we calculated its sensitivity (number of methylation-positive cancer cases/number of total cancer cases) and speci city (number of methylation-negative benign cases/total number of benign cases) in CRC. As shown in Table 2 , the sensitivity for cancer detection using SFRP2 methylation in tissue, fecal and serum DNA was similar, ranging from 66.9 to 88.2%. In contrast, the speci cities in distinguishing CRCs from benign adenomas varied greatly, 34.9%, 54.0%, and 93.7% for SFRP2 methylation in tissue, fecal and serum DNA samples, respectively. ese data revealed the potential diagnostic value of serum SFPR2 methylation in CRC.
Tang et al. Clinical signi cance of SFRP2 methylation in CRC
e correlation between SFRP2 methylation status and the clinicopathologic parameters of CRC was examined. e SFRP2 methylation in tumor tissue was signi cantly correlated with poor di erentiation grade (P=0.026) and serosal/ Prognostic signi e association of SFRP2 methylation status with clinical outcome was analyzed in 77 CRC patients for whom follow-up information was available. e overall survival curves of the patients were shown in Figure 2 . Patients with SFRP2 hypermethylation in tumor, stool and serum samples had a signicantly shorter overall survival than patients without SFRP2 methylation (P=0.0216, 0.0219 and 0.0255, respectively; logrank test). Univariate analysis showed that poor tumor di erentiation (P=0.013), serosal/subserosal invasion (P=0.012), lymph node metastasis (P<0.001), advanced TNM stages (P=0.033), as well as SFRP2 promoter methylation in tumor (P=0.030) and serum (P=0.028) DNA, were signi cant prognostic factors (Table 4 ). e multivariate analysis further revealed that the serosal/subserosal invasion, lymph node metastasis and SFRP2 promoter methylation in tumor samples were independent prognostic factors ( Table 4) .
Discussion
Epigenetic silencing of tumor suppressor genes has been increasingly recognized as a causative mechanism in tumorigenesis. Accumulating evidence indicates that SFRP2, an important member of the SFRP family, functions as a negative regulator of the oncogenic Wnt pathway through competing with frizzled membrane-bound receptors [18, 19] . In a broad range of malignancies including CRC, epigenetic inactivation of SFRP2 by promoter methylation is frequently detected [17, [20] [21] [22] [23] . Here we demonstrated that SFRP2 hypermethylation mostly frequently occurred in CRC patients, followed by patients with advanced adenomas and hyperplastic polyps. Normal controls, however, displayed an extremely low incidence of SFRP2 methylation. It is noteworthy that hypermethylation of SFRP2 gene was found in two endoscopically normal subjects, which was likely attributed to the presence of premalignant lesions. A previous study reported that the apparently normal mucosal eld of patients with neoplasia had undergone epigenetic modi cation of a large number of genes, including SFRP2 [28]. ese ndings suggest that SFRP2 methylation is closely linked to the initiation and progression of CRC carcinogenesis. erefore, examination of SFRP2 methylation status may provide useful information for detecting the early onset of CRC.
To further explore the clinical relevance of SFRP2 methylation in CRC, the sensitivity and speci city of this potential diagnostic marker was evaluated. e results revealed similar high sensitivities for cancer detection using SFRP2 methylation in tissue, fecal and serum DNA samples, ranging from 66.9 to 88.2%; however, the speci cities in distinguishing CRCs from benign adenomas varied greatly, from ranging from 34.9% to 93.7%. Examination of the correlation between SFRP2 methylation and the clinicopathologic parameters of CRC further revealed that SFRP2 methylation in tumor tissue and fecal DNA samples was signi cantly correlated with poor di erentiation grade and serosal/subserosal invasion. Interestingly, serum SFRP2 methylation seems more informative, which was found to be signi cantly associated not only with poor di erentiation grade and serosal/subserosal invasion, but also with lymph node metastasis status and TNM stage. Hypermethylation of SFRP2 in serum DNA was strongly correlated with shorter overall survival in CRC patients, as were the levels in tissue and fecal DNA. Moreover, SFRP2 promoter methylation in tumor samples was an independent prognostic predictor of overall survival. Based on these ndings in this cohort of patients, serum SFRP2 hypermethylation appears to be a promising diagnostic and prognostic marker of CRC. Further investigation using a larger cohort of patients is needed to con rm this view. um DNA samples, respectively. HR, hazard ratio; 95% C CI, 95% con dence Previous studies have documented that DNA methylation of various genes in serum and plasma can be highly speci c biomarkers for several human cancers [29, 30] . Although the exact origins of this circulating cell-free DNA remain unknown, it has been proposed to be derived from apoptotic and necrotic cells [31] . In the present study, patients with precancerous lesions showed a signi cantly lower rate of SFRP2 methylation in serum DNA than that in tissue DNA. In contrast, SFRP2 methylation could be detected in serum DNA of patients with CRC at a similar incidence to that in tumor DNA. Moreover, serum SFRP2 methylation was signi cantly correlated with lymph node metastasis status and TNM stage. Given these ndings, we speculated that hypermethylated SFRP2 in serum could re ect the nature of CRC, and with the progression of the disease, more tumor cells might acquire the ability to invade and metastasize through the lymphatic and blood system, thus leading to the increased production of methylated SFRP2 from disseminated cancer cells.
In summary, our data highlight the diagnostic and prognostic value of SFRP2 methylation in CRC. Hypermethylation of SFRP2 in serum DNA can serve as a potential, non-invasive marker for early detection and staging of CRC. Hypermethylated SFRP2 promoter may predict poor prognosis in patients with CRC.
